Summary Exposure of the cranium to white light in mice that had been given haematoporphyrin derivative (HpD) led to a rapid onset of vasogenic cerebral oedema, cerebral necrosis, coma and death. Selectivity of the initial damage for endothelium was suggested by (a) early breakdown (<1 h) of the blood-brain barrier (BBB) as shown by increased permeability to Evans blue (b) separation and increased vesiculation of endothelial cells at 2h and (c) endothelial cell pyknosis at 3-4h in small vessels next to apparently undamaged neurones and neuroglia. There was no damage to myelin sheaths, and astrocytes showed only end-feet oedema, a reaction to exudation of protein-rich fluid. Within a few hours of illumination, most cells in the illuminated area were necrotic. Cerebral photosensitivity persisted for at least 12 weeks after a single injection of HpD. Our results suggest that the primary site of damage in the brain is the endothelium of small vessels, and that HpD remains associated with this for a remarkably long time. These findings are relevant to the mechanisms by which photodynamic therapy damages other tissues, including neoplasms, and particularly to the possible application of this treatment to brain tumours.
The prognosis of malignant brain tumours is poor. In spite of radical surgery, radiotherapy and chemotherapy, 80-90% of patients die within 2 years of initial treatment and the few that live more than 2 years often have diffuse cortical dysfunction induced by radiation or chemotherapeutic agents (Lieberman et al., 1982) . There is thus a pressing need for new treatments, and photodynamic therapy (PDT) is one that deserves examination. This treatment depends on the fact that some photosensitisers, such as haematoporphyrin derivative (HpD) , localise in and are retained by tumours (and many normal tissues) after systemic administration. Sites of localisation are photosensitive, and exposure to sufficiently intense light of appropriate wavelengths causes rapid cell necrosis. The brain appears to be a promising site for PDT as examination by fluorescence has suggested that haematoporphyrin does not cross the blood-brain barrier (BBB) whereas it does enter brain tumours (Wise & Taxdal, 1967) . Further, the brain has favourable optical properties. At the red wavelengths used to excite HpD, attenuation of light by brain tissue is considerably less than that by other tissues such as muscle, kidney or liver (Svaasand et al., 1981) . These facts, together with the fact that brain neoplasms kill by local growth rather than by metastasis, raise the possibility of their complete eradication by PDT. Correspondence: M.C. Berenbaum. Received 17 June 1985; and in revised form, 13 September 1985. We therefore investigated the effects of PDT in mice bearing cerebral transplants of the PC6 myeloma. We were surprised to find that such animals, given HpD intravenously and subsequently subjected to cranial illumination (skin reflected) from a xenon arc, died within a few hours. Nontumour bearing mice behaved similarly. It therefore appeared, contrary to belief at that time, that normal brain could be photosensitised by systemically administered porphyrins. This finding was relevant, not only to the use of PDT in treating brain tumours, but also to the mechanisms, still obscure, by which PDT causes tumour.necrosis.
We have now investigated the phenomenon in more detail. A preliminary account of this work has already appeared (Bonnett et al., 1984) . Subsequently, our attention was drawn to work on similar lines by Rounds et al. (1982) .
Materials and methods Animals
Female BALB/c mice, weighing 18-25 g, were used (the effect is however, neither strain-nor speciesspecific).
Haematoporphyrin derivative This was a gift from Dr T.J. Dougherty. It was dissolved at a concentration of 4mgml-1 in 0.5% (w/v) sodium hydrogen carbonate in PBS, stirred at room temperature for 3h and then stored in the (j The Macmillan Press Ltd., 1986 refrigerator, where it remained active for at least a year. The dose was 40mgkg-1 i.v. except where otherwise stated, equivalent on a surface area basis to about 3 mg kg-1 in man.
Treatment
Mice were anaesthetised with 'Equithesin' (Green, 1979) diluted 1 in 3 with 0.15 M saline and given in a dose of 10mlkg-1 i.p. An incision was made from the snout to the base of the skull and the cranium, kept wet with PBS, was exposed to light from a 900W xenon arc (Applied Photophysics). Light was passed through 10cm water, 2cm of 1% copper sulphate, a Calflex BI/Kl heat-reflecting filter (Balzer's High Vacuum) and a 3mm heatabsorbing filter 4602 (Optical Instruments Series) to remove heat. Light from this system appeared white. Its spectral distribution was maximal at 500 nm, with 50% peak intensities at 390 and 590 nm. Light intensity measured with a 14BT thermopile (Laser Instrumentation) varied from 128 to 180 mW cm -2 in different experiments. Maximum light doses in sensitised mice were 80J cm-2 (illumination times of 7-11 minutes) and in unsensitised mice 300 Jcm-2. After illumination the incision was sutured and mice were left to recover at 37°C.
Histology
For conventional histology, mice were killed with ether, brains were fixed in formol-saline and paraffin sections stained with haematoxylin and eosin. For electron microscopy, anaesthetised mice were superperfused through the left cardiac ventricle at a pressure of 110-120mmHg with 3% glutaraldehyde in 0.1 M sodium cacodylate. Brains were then removed and pieces of cerebral cortex 1 x 1 x 3mm placed in cold fixative for a further 20 min, post-fixed in 1% osmium tetroxide in 0.1 M cacodylate buffer and bulk-stained in 0.25% uranyl acetate for 20 min. Sections of resin-embedded material were cut on a Cambridge Huxley ultramicrotome, stained with lead citrate and examined under a Hitachi H300 electron microscope.
Permeability of blood-brain barrier Mice were given 0.2 ml i.v. of 2% Evans blue (Merck) in 10% bovine serum albumin in PBS (Klatzo & Steinwall, 1965) and killed with ether 1 h later, except where otherwise stated. The brain was removed and broken up with a pestle in 20 ml of a 30:50 mixture of 0.5% aqueous sodium sulphate and acetone (Harada et al., 1970) . After 24 h at room temperature the extract was centrifuged at 1000 r.p.m. for 10 min and absorption of the supernatant measured at 620 nm on a CE373 Linear Readout Grating Spectrophotometer (Cecil Instruments) . The amount of Evans blue in the brain was read off a calibration curve constructed with standard solutions of the dye in the extracting solvent. Student's t-test (one-tailed) was used to assess the significance of increases in brain dye content.
Results

Clinical course
This depended on the doses of HpD and light and the interval between them. For example, animals that had been given 40mg kg-' HpD and illuminated 24h later with 40J cm-2 (about four times the LD100, see Figure 1 ) seemed normal for -1 h after recovery from anaesthesia, became sluggish by 2-3 h, comatose at 4-5 h and usually died between 4.5 and 6 h (with occasional deaths up to 24 h). With lower light or HpD doses and with longer intervals between them, the onset of abnormal signs was delayed and mice sometimes remained comatose for several hours before death or recovery. However, nearly all deaths in these experiments occurred within 48 h of illumination. Figure 1 shows mortality at 48 h in mice given different light doses at various intervals after HpD. At one day after injection there was high photosensitivity, exposure to as little as 10Jcm-2 (-1 min illumination) being almost uniformly lethal. Sensitivity fell slowly with time, and was still high at 2 weeks, when the 48 h LD50 was 12.5 Jcm-2. It is notable that lethal photosensitivity persisted for at least 12 weeks (the maximum period of study), when the LD50 was llOJcm-2. Mice not given HpD suffered no ill-effects from cranial illumination, even with doses of 300 J cm Permeability of blood-brain barrier When Evans blue was injected into untreated mice, the brain removed 1 h later showed a faint and uniform blueing throughout, and the choroid plexuses were pale blue. These brains contained -1 Mg of dye and, as they weighed on average 0.4 g and the blood level of Evans blue was -90pgml-1, the brain content can thus largely be accounted for by intravascular dye, with the brain blood volume of 2-3% typical of small mammals (Levine et al., 1984; Picozzi et al., 1985) .
The brains of HpD-sensitised mice exposed to light showed in addition deep staining of the illuminated region (Figure 2 ). Deeply stained regions often showed a central paler area. Experiments with shields showed that staining was sharply confined to the illuminated area, and it was limited to the superficial 1-2mm of the cerebrum a b or cerebellum (Figure 2b ). Staining was first consistently seen 1 h after illumination (in mice given Evans blue immediately after illumination). As the interval between illumination and dye injection was lengthened, staining of the brain increased in intensity and reached a maximum in mice injected at 3 h and killed at 4 h.
In the experiments described here, the maximum rise in brain levels of Evans blue was up to 3-5 times that of controls but, for a proper appreciation of this rise, the mainly intravascular background level of 1 Mg/brain should be subtracted and it should further be borne in mind that probably less than a third of the brain volume was involved in these changes (Figure 2b ), so that the proportionate rise in permeability in the damaged area was considerably greater than indicated by these overall values. It is therefore not surprising that naked eye inspection of the brain was a more sensitive method for detecting photosensitisation than measurement of total brain dye content, although it was not quantitative. Figure 4 shows the relation between light dose and Evans blue content in mice illuminated at various times after HpD injection. Mice not given HpD and exposed to 40 or 80 J cm2 light showed no visible increase in blueing as compared with controls, and no significant rise in Evans blue content. In HpD-sensitised mice there were doserelated increases in HpD content. In mice illuminated 1 day after sensitisation, even the smallest dose of light, 2.5 J cm-2, caused significantly increased permeability to Evans blue (P <0.05). With increasing interval between HpD injection and illumination, the dose-effect curves were progressively shifted to the right so that, at 10 days, it required about 2.5-3 times as much light as at 1 day to produce equivalent increases in permeability and, at 23 days, the required increase was 6-8 fold. All HpD-sensitised brains illuminated When the dose of HpD was varied ( Figure 5 ) and a fixed dose of light (40 J cm 2) given, significant (P < 0.05) rises in whole brain Evans blue content were produced only with HpD doses of . 20 mg kg-1. However, increased blueing on naked-eye inspection was seen in all brains illuminated at 1 or 7 days after .10mg kg-of HpD. Again sensitisation decreased with time but there was only a small shift to the right in the doseeffect curve between 1 and 7 days after sensitisation, suggesting that a considerable proportion of the HpD remained at its site of action over that period. Damage was first evident 3-4.5 h after illumination, when there was oedema and patchy pyknosis of neurones and neuroglia ( Figure 6 ). Petechial haemorrhages were often seen after 7-9 h. A striking finding was pyknosis of endothelial nuclei in small vessels at 3-4 h and, at the edges of the oedematous areas, this was seen even when immediately contiguous neurones and neuroglia showed little evidence of damage (Figure 7) . In mice surviving treatment and killed one week later, Figure 6 Brain of mouse given HpD, 40mg kg1 and exposed to 50 J cm-2 light 4 days later. Brain removed 3.5 h after illumination. Note oedema, pyknotic neurones and neuroglia. The area to the left was outside the illuminated field and appears normal.
(H&E x 225). there were areas of necrosis in the cerebral cortex, with surrounding microglial reaction and ingrowth of capillaries (Figure 8 ). Electron microscopy The cerebral cortex of untreated mice and those subjected to the operative procedure and illumination without sensitisation was generally well fixed, and the fine structure of the capillary endothelium was normal. Well defined intercellular junctions were present and only occasional small vesicles similar to pinocytotic vesicles were present in the cells. The capillary basal lamina, associated astrocyte end-feet and neuronal perikaryon and axons were all structurally normal (Figure 9a) .
In sensitised and illuminated brains, the perfusion of the cortex was generally less satisfactory than in controls. In well-perfused areas, 30 min after illumination, there was no change in the appearance of the capillary endothelium, but there was some oedema of capillary-associated astrocyte end-feet. At 2 h astrocyte end-feet oedema was markedly increased (Figure 9b ) and, in some vessels identified as post-capillary venules by the presence of pericytes, there was also separation of individual endothelial cells from one another (Figure 9c ). Three to four hours after exposure to light, separation of endothelial cells was frequently seen in the venules, but not in the capillaries. Necrosis of endothelium was occasionally observed in isolated capillaries but not thrombosis. Astrocyte end-feet oedema was much more pronounced than at 2 h, and was seen around both large and small vessels. At 2-3 h after illumination, small numbers of membrane-bounded vacuoles were often present in endothelial cells of capillaries and post-capillary venules (Figure 9d ). Such vacuoles were also seen in neuronal perikarya and processes, but there was no evidence at any time of an increase in the width of the intercellular space between adjacent cell processes. 
Discussion
It is currently widely accepted that the BBB is located at the level of the endothelium of the cerebral vessels. Two possible routes of transfer of large molecules across capillary endothelium exist: (i) through intercellular spaces and (ii) through small vesicles formed by endocytosis at one surface of the cells and released by exocytosis at the other, possibly forming transient channels across the endothelial cells (transcytosis). Except in the choroid plexuses and certain periventricular areas such as the area postrema and the pituitary stalk, where the BBB is deficient (Bradbury, 1979) , intercellular passage is prevented by the presence of tight junctions, and vesicles of the size of pinocytotic vesicles are only occasionally present in cerebral endothelial cells. Thus, neither route is effectively utilised in most areas of the normal brain.
When we began this work, the prevailing belief, based on experiments with haematoporphyrin and other porphyrins (Wise & Taxdal, 1967; Winkelman et al., 1967) was that the BBB was impermeable to porphyrins. Nevertheless, the experiments reported here show that the brain is undoubtedly photosensitised by HpD, so either the prevailing belief is wrong or, if it is not, sensitisation must be effected by porphyrin on the vascular side of the barrier.
Since the early work of Wise & Taxdal (1967) , based on naked-eye fluorescence, several investigators have examined the distribution of HpD in normal brain and brain tumours by more sophisticated fluorescence methods or by using isotopically labelled HpD. With these methods, small amounts of HpD are found in the normal brain at least up to 72h after injection (Gomer et al., 1982; Wharen et al., 1983; Boggan et al., 1984) . However, these studies do not resolve the problem, for two reasons. First, even if the BBB fully excluded HpD from neural tissue, some will still be present in the blood at least up to 72 h after injection (Gomer & Dougherty, 1979; Gomer et al., 1982) . Moreover, the choroid plexuses and some periventricular regions lack a BBB, and the barrier can also be circumvented by uptake of materials at peripheral axon endings followed by retrograde transport to cranial nerve nuclei (Broadwell & Brightman, 1976) . Thus, sensitive assays on whole brains or macroscopic portions of brain will inevitably reveal the presence of small amounts of HpD, but will not show whether it has passed through the BBB or not.
Second, HpD is a complex mixture, only a fraction of which has biological activity in vivo (Bonnett et al., 1981; Berenbaum et al., 1982) . The biologically active fraction is probably a dimer or oligomer (Berenbaum et al., 1982; Bonnett et al., 1984; Dougherty et al., 1984) on the vascular side of the barrier, whether this is in the blood or associated with the endothelium.
So far as circulating intravascular material is concerned, although this might partly be responsible for sensitisation during the first few days after injection, it is almost inconceivable that it could still be present in effective amounts three months later (Figure 1) . It is certainly possible that lipophilic constituents of HpD might cross the BBB and be retained for long periods in extravascular sites such as myelin sheaths or astrocytes, in which case these would be the primary sites of damage, and vascular damage and breakdown of the BBB would occur secondarily, perhaps by release of prostaglandins or free fatty acids (Bhakoo et al., 1984a,b) . It is also conceivable that active material might be retained on or in the endothelium, in which case the primary lesion would be vascular.
Our experiments tend to support the second possibility, for three reasons. First, the rapid entry of Evans blue into illuminated areas of brain suggests that the oedema was of the vasogenic, not cytotoxic type (Klatzo, 1967) , that is, the primary lesion involved the vessel wall and not extravascular structures. Second, conventional microscopy showed early damage to endothelial cells, sometimes while neighbouring neurones and neuroglia appeared intact (Figure 7) . Endothelium is generally believed to be considerably more resistant to a variety of insults than neurones and neuroglia and, had the initial damage been extravascular, and endothelial damage secondary to this, we would not have expected to see this anomalous distribution of damage. Lastly, electron microscopy showed no clear evidence of damage to neurones or myelin sheaths other than that attributable to impaired perfusion and fixation, and changes in astrocytes were limited to end-feet oedema, which can be attributed to uptake of protein-rich exudate from the vessels (Bradbury, 1979) . On the other hand, significant changes were seen 2h after illumination in the endothelium, viz., separation of endothelial cells in post-capillary venules and increased vesiculation of endothelium. (Separation of endothelial cells in post-capillary venules rather than in capillaries may be related to a greater lability of tight junctions in the former. This lability has been related to the presence on venular endothelium of numerous histamine H2 receptors (Heltianu et al., 1982) ). Although we did not find endothelial cell separation in capillaries, this does not exclude the possibility that PDT disrupts tight junctions in these vessels also, but to a degree not detectable by our methods. The increased numbers of vacuoles seen in endothelial cells suggests that bulk transport of fluid through these cells may also play a role in oedema formation here. Precise identification of the sites of transport across the BBB can be obtained only by application of appropriate tracer techniques. Star et al. (1984) , Selman et al. (1984) and Henderson et al. (1985) found evidence for a rapid onset of vascular damage in HpD-sensitised tumours also, as indicated by vasoconstriction and reduction in blood flow and gross haemorrhage within 10-15min of illumination, and Chopp et al. (1985) found changes in nuclear magnetic resonance spectra suggestive of anoxia. However, in these experiments, tumours were illuminated 24 h after HpD injection (4 h in the work of Chopp et al., 1985) ), when substantial amounts of HpD would have been present in the blood, and so photosensitisation effects in circulating blood cannot be excluded. Nevertheless, these experiments and the work reported here add weight to the suggestion that tumour blood vessels, and especially their endothelium, may represent a highly vulnerable target for anti-tumour therapy (Denekamp et al., 1983) .
A number of attempts have been reported of PDT in cerebral tumours in man (Forbes et al., 1980; Laws et al., 1981 Laws et al., , 1985 McCulloch et al., 1984; Ling et al., 1985) . These were tentative explorations, and do not allow conclusions to be drawn as to the efficacy of the treatment. One group (McCulloch et al., 1984) reported that the main complication of treatment was cerebral oedema whereas Laws et al. (1985) and Ling et al. (1985) observed no evidence of significant oedema or other adverse effects. However, no group has yet reported a significant therapeutic effect with the PDT regimens used, and the conclusion of Laws et al. (1985) that PDT is within the limits of safety for the patient therefore begs the question as to whether therapeutically effective PDT is also safe. It is relevant that Boggan et al. (1984) found that PDT with HpD in rats with intracerebral transplants of the 9L tumour did not prolong survival, and that rats that died after treatment had brain oedema which they thought the likely cause of death. It is likely that the most useful application of PDT in brain tumours will be, not as a sole therapy to destroy large tumours, but to eradicate tumour cells remaining after surgical resection, which are responsible for recurrence and which usually invade surrounding normal brain to a considerable distance. When used in this way, PDT that is therapeutically effective without causing unacceptable damage to normal brain will be feasible only if treatment is fairly selective for neoplastic as compared with normal tissue. The experiments described here suggest that it might be difficult or impossible to obtain the required degree of selectivity with HpD. Effective and acceptable PDT may thus depend on finding photosensitisers with reduced ability to sensitise normal brain, and a search for these is in progress.
